Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Should You Buy This Growth Stock Following a Major Approval?

TheMotleyFool

0 0

Should You Buy This Growth Stock Following a Major Approval?: https://g.foolcdn.com/editorial/images/697309/patient-sitting-on-hospital-bed.jpg

The past three years have been a southbound roller coaster for Bluebird Bio (NASDAQ: BLUE). The small-cap biotech encountered a series of headwinds, losing 90% of its value. But Bluebird hasn't said its last word -- and it recently earned an important approval in the U.S. that could help it turn things around.

Should investors consider purchasing shares of this beaten-down biotech stock now? Let's look into what Bluebird's recent approval means for the company's overall prospects.